FuturedMe was introduced in Nikkei Biotechnology & Business Online as “ creating new medical drugs with innovative target protein degradation technology and having raised around 700 million yen as Series A.”

https://bio.nikkeibp.co.jp/atcl/news/p1/19/06/06/05674/